argenx SE

NASDAQ (USD): argenx SE (ARGX)

Last Price

360.23

Today's Change

+1.82 (0.50%)

Day's Change

357.55 - 362.50

Trading Volume

322,389

Profile
ARGX

Exchange:  NASDAQ Global Select NASDAQ Global Select

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc. Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc.

Full Time Employees:  1,148 1,148

IPO Date:  2017-05-18 2017-05-18

CIK:  0001697862 0001697862

ISIN:  US04016X1019 US04016X1019

CUSIP:  04016X101 04016X101

Beta:  0.35 0.35

Last Dividend:  0.00 0.00

Dcf Diff:  19.58 19.58

Dcf:  400.48 400.48

Description

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Address

Willemstraat 5,
Breda, 4811 AH, NL

31 10 703 8441

http://www.argenx.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment